Comparison · NCT00753714-d1d2c366
ZD6474 ( (Vandetanib),Gemcitabine vs Placebo to Match ZD6474 (Vandetanib),Gemcitabine: Overall Objective Response
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ZD6474 ( (Vandetanib),Gemcitabine vs Placebo to Match ZD6474 (Vandetanib),Gemcitabine: Overall Objective Response. Trial comparisons, record NCT00753714-d1d2c366. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00753714-d1d2c366
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.148 | 0.0796 | 0.257 | wilson | |
| Risk in group 2 | 0.127 | 0.0658 | 0.231 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0206 | -0.104 | 0.146 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.16 | 0.48 | 2.81 | log | |
| Odds ratio, group 1 over group 2 | 1.19 | 0.427 | 3.32 | log | |
| Number needed to treat, for one more participant with the outcome on ZD6474 ( (Vandetanib),Gemcitabine than on Placebo to Match ZD6474 (Vandetanib),Gemcitabine | 48.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ZD6474 ( (Vandetanib),Gemcitabine | Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued. | 9 | 61 | OG000 |
| Group 2 | Placebo to Match ZD6474 (Vandetanib),Gemcitabine | Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1. . Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued. | 8 | 63 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Overall Objective Response
- Description
- Time frame
- Oct 2008- dec 2011
- Population
Source ClinicalTrials.gov
Trial
- Title
- Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine
- NCT number
- NCT00753714
- Phases
- PHASE2
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- ZD6474, Vandetanib, Placebo to Match ZD6474, Vandetanib, Gemcitabine
- Lead sponsor
- Genzyme, a Sanofi Company
- Results first posted
- 2012-09-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00753714?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00753714-d1d2c366